ANI Pharmaceuticals (NASDAQ:ANIP) Releases FY 2025 Earnings Guidance

ANI Pharmaceuticals (NASDAQ:ANIP) updated its FY 2025 earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of 6.120-6.490 for the period, compared to the consensus estimate of 5.560. The company issued revenue guidance of $756.0 million-$776.0 million, compared to the consensus revenue estimate of $724.9 million.

ANI Pharmaceuticals Stock Up 0.9 %

NASDAQ ANIP opened at $59.68 on Thursday. The stock has a market cap of $1.26 billion, a PE ratio of -108.51 and a beta of 0.74. ANI Pharmaceuticals has a fifty-two week low of $52.50 and a fifty-two week high of $70.81. The business has a 50 day moving average price of $57.42 and a two-hundred day moving average price of $58.10. The company has a quick ratio of 1.97, a current ratio of 2.74 and a debt-to-equity ratio of 1.52.

Analysts Set New Price Targets

Several research firms have recently commented on ANIP. Leerink Partners began coverage on ANI Pharmaceuticals in a research note on Wednesday, December 11th. They set an “outperform” rating and a $80.00 target price for the company. Leerink Partnrs upgraded ANI Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, December 11th. StockNews.com cut ANI Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday. HC Wainwright reiterated a “buy” rating and set a $94.00 target price on shares of ANI Pharmaceuticals in a research note on Monday. Finally, Guggenheim increased their target price on ANI Pharmaceuticals from $84.00 to $86.00 and gave the company a “buy” rating in a research note on Wednesday. One investment analyst has rated the stock with a sell rating, one has given a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $79.00.

Insiders Place Their Bets

In other news, SVP Krista Davis sold 1,000 shares of the firm’s stock in a transaction on Wednesday, December 11th. The stock was sold at an average price of $60.00, for a total transaction of $60,000.00. Following the transaction, the senior vice president now directly owns 49,059 shares of the company’s stock, valued at approximately $2,943,540. This trade represents a 2.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Stephen P. Carey sold 7,500 shares of the firm’s stock in a transaction on Tuesday, December 17th. The shares were sold at an average price of $55.79, for a total value of $418,425.00. Following the transaction, the chief financial officer now directly owns 154,468 shares in the company, valued at $8,617,769.72. This trade represents a 4.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 10,300 shares of company stock valued at $584,009 over the last three months. Company insiders own 12.70% of the company’s stock.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.